KCT0006861
Not yet recruiting
未知
One-Month Dual Antiplatelet Therapy followed by Potent P2Y12 Inhibitor Monotherapy After Orsiro Mission® Stent Implantation in Patients with Acute Coronary Syndrome: DAPT-SIRO TRIA
ConditionsDiseases of the circulatory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the circulatory system
- Sponsor
- Chonnam National University Hospital
- Enrollment
- 2000
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adults 19 years of age or older
- •2\) Acute coronary patients who had successful percutaneous coronary intervention (PCI) with Orsiro Mission® stent
- •3\) Subjects who agree to the research protocol and clinical follow\-up plan, decide voluntarily to participate in this clinical study, and agree in writing to the subject consent form
Exclusion Criteria
- •1\) Subjects with known hypersensitivity or contraindication to the following drugs or substances: heparin, aspirin, prasugrel, ticagrelor, sirolimus, contrast agent
- •2\) If you are taking anticoagulants: warfarin, apixaban, rivaroxaban, dabigatran, edoxaban
- •3\) In case of previous myocardial infarction or coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
- •4\) Subjects with a transient ischemic attack (TIA) or stroke
- •5\) Subjects of fertile age who are planning to become pregnant or cannot rule out the possibility of pregnancy during the study period
- •6\) Subjects whose remaining life expectancy is less than 1 year
- •7\) Subjects who visited the hospital due to cardiac arrest or psychogenic shock and whose survival is predicted to be low by medical judgment
- •8\) Complex lesions – unprotected left main lesions, chronic obstructive lesions, severely calcified or tortuous lesions
- •9\) You are participating in another randomized controlled study, or you are participating in an observational study that may affect the study.
- •10\) In case the researcher judges that it is not suitable for this clinical study or may increase the risk related to research participation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
One-Month Dual Antiplatelet Therapy followed by P2Y12 Inhibitor Monotherapy After Biofreedom Ultra® Stent Implantation in Patients with Acute Coronary Syndrome: DAPT-FREE TRIAKCT0006530Chonnam National University Hospital1
Completed
Not Applicable
Impact of 1-month Dual Antiplatelet Therapy After Treatment with Drug-Coated Balloon for Femoropopliteal Artery DiseaseArteriosclerosis obliteransJPRN-UMIN000034867Hyogo College of Medicine151
Recruiting
Not Applicable
Safety and efficacy of 1-month dual antiplatelet therapy in high bleeding and ischemic risk elderly patients with coronary artery disease after implantation of zotarolimus-eluting coronary stent system (Resolute Onyx™ , Medtronic, Minneapolis, MN); A multicenter, prospective, observational studyFactors influencing health status and contact with health servicesKCT0008377Pusan National University Yangsan Hospital500
Completed
Not Applicable
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
Active, not recruiting
Phase 1
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78